$ZEOX
Zeo ScientifiX, Inc. Stock $zeox

$zeox Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000182912624001677 Filed on March 18, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$1.154M	$1.070M
YoY Change	7.83%	-33.08%
Cost Of Revenue	$159.0K	$104.3K
YoY Change	52.43%	-30.05%
Gross Profit	$995.0K	$965.9K
YoY Change	3.01%	-33.39%
Gross Profit Margin	86.22%	90.25%
Selling, General & Admin	$2.157M	$3.142M
YoY Change	-31.35%	1.64%
% of Gross Profit	216.78%	325.31%
Research & Development	$27.00K	$194.7K
YoY Change	-86.13%	-29.53%
% of Gross Profit	2.71%	20.16%
Depreciation & Amortization	$19.00K	$155.8K
YoY Change	-87.8%	999.51%
% of Gross Profit	1.91%	16.13%
Operating Expenses	$27.00K	$194.7K
YoY Change	-86.13%	-93.7%
Operating Profit	-$1.162M	-$2.176M
YoY Change	-46.61%	32.59%
Interest Expense	$27.00K	$60.97K
YoY Change	-55.71%	-251.28%
% of Operating Profit
Other Income/Expense, Net	$149.0K	-$49.39K
YoY Change	-401.68%	311.58%
Pretax Income	-$1.040M	-$2.287M
YoY Change	-54.52%	35.01%
Income Tax
% Of Pretax Income
Net Earnings	-$1.040M	-$2.287M
YoY Change	-54.52%	35.01%
Net Earnings / Revenue	-90.12%	-213.66%
Basic Earnings Per Share	-$0.17	-$0.33
Diluted Earnings Per Share	-$0.17	$0.00
COMMON SHARES
Basic Shares Outstanding	6.125M shares	1.464B shares
Diluted Shares Outstanding	6.191M shares	7.010M shares

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.172M	$1.423M
YoY Change	-17.61%	846.31%
Cash & Equivalents	$1.172M	$1.423M
Short-Term Investments
Other Short-Term Assets	$315.0K	$714.7K
YoY Change	-55.93%	461.72%
Inventory	$316.0K	$281.3K
Prepaid Expenses	$315.0K	$214.7K
Receivables	$77.00K	$106.9K
Other Receivables	$12.00K	$8.000K
Total Short-Term Assets	$1.892M	$2.652M
YoY Change	-28.67%	384.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$533.0K	$1.544M
YoY Change	-65.48%	4.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.000K	$30.40K
YoY Change	-76.97%	-39.54%
Total Long-Term Assets	$540.0K	$1.665M
YoY Change	-67.58%	8.77%
TOTAL ASSETS
Total Short-Term Assets	$1.892M	$2.652M
Total Long-Term Assets	$540.0K	$1.665M
Total Assets	$2.432M	$4.318M
YoY Change	-43.67%	107.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.219M	$2.268M
YoY Change	-2.18%	15.91%
Accrued Expenses		$83.97K
YoY Change		-95.46%
Deferred Revenue
YoY Change
Short-Term Debt	$663.0K	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$663.0K
YoY Change
Total Short-Term Liabilities	$3.923M	$3.426M
YoY Change	14.51%	-30.77%
LONG-TERM LIABILITIES
Long-Term Debt	$17.00K	$207.8K
YoY Change	-91.82%	-32.83%
Other Long-Term Liabilities		$7.190K
YoY Change		-93.37%
Total Long-Term Liabilities	$17.00K	$215.0K
YoY Change	-92.09%	-48.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.923M	$3.426M
Total Long-Term Liabilities	$17.00K	$215.0K
Total Liabilities	$3.940M	$3.641M
YoY Change	8.22%	-32.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.55M	-$52.81M
YoY Change	10.87%
Common Stock	$6.000K	$1.489M
YoY Change	-99.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.508M	$677.0K
YoY Change
Total Liabilities & Shareholders Equity	$2.432M	$4.318M
YoY Change	-43.67%	107.67%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$1.040M	-$2.287M
YoY Change	-54.52%	35.01%
Depreciation, Depletion And Amortization	$19.00K	$155.8K
YoY Change	-87.8%	999.51%
Cash From Operating Activities	-$575.0K	-$1.283M
YoY Change	-55.17%	129.06%
INVESTING ACTIVITIES
Capital Expenditures		$16.12K
YoY Change		-110.39%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$16.12K
YoY Change		-89.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$9.000K	-$1.032M
YoY Change	-99.13%	-236.32%
NET CHANGE
Cash From Operating Activities	-$575.0K	-$1.283M
Cash From Investing Activities		-$16.12K
Cash From Financing Activities	-$9.000K	-$1.032M
Net Change In Cash	-$584.0K	-$2.331M
YoY Change	-74.94%	-5680.93%
FREE CASH FLOW
Cash From Operating Activities	-$575.0K	-$1.283M
Capital Expenditures		$16.12K
Free Cash Flow	-$575.0K	-$1.299M
YoY Change	-55.73%	220.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	ZEOX	Initial Purchase Order InitialPurchaseOrder		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-01-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	000-55008
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Zeo ScientifiX, Inc.
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--10-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001557376
CY2023Q1	us-gaap	Other Income OtherIncome		usd
CY2024Q1	ZEOX	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation		usd
CY2024Q1	ZEOX	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2024Q1	ZEOX	Cancellation Of Shares In Connection With Litigation CancellationOfSharesInConnectionWithLitigation		usd
CY2024Q1	ZEOX	Change In Commitments Fee Shortfall Obligation ChangeInCommitmentsFeeShortfallObligation		usd
CY2024Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties		usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2024Q1	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	ZEOX	Funds Held In Escrow For Share Repurchase FundsHeldInEscrowForShareRepurchase		usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	ZEOX	Reduction In Accounts Payable For Equipment Returned To Vendor ReductionInAccountsPayableForEquipmentReturnedToVendor		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 246
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Davie
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33314
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4180540
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3321 College Avenue
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57034000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	56260000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58548000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57508000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1508000	usd
CY2024Q1	dei	City Area Code CityAreaCode	888
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	963-7881
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6125482	shares
CY2024Q1	us-gaap	Cash Cash	1172000	usd
CY2023Q4	us-gaap	Cash Cash	1756000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	77000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	315000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	106000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	316000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	310000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1892000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2202000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	533000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573000	usd
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	7000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	7000	usd
CY2024Q1	us-gaap	Assets Assets	2432000	usd
CY2023Q4	us-gaap	Assets Assets	2782000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2219000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2612000	usd
CY2024Q1	ZEOX	Advances Payable Current AdvancesPayableCurrent	221000	usd
CY2023Q4	ZEOX	Advances Payable Current AdvancesPayableCurrent	221000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	10000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	23000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	62000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	68000	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	663000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	657000	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	810000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	497000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3923000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4010000	usd
CY2024Q1	ZEOX	Long Term Finance Lease Obligations LongTermFinanceLeaseObligations	17000	usd
CY2023Q4	ZEOX	Long Term Finance Lease Obligations LongTermFinanceLeaseObligations	13000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	3940000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4023000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6125482	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6125482	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7283483	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7283483	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1241000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2432000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2782000	usd
CY2024Q1	ZEOX	Revenues From Related Parties RevenuesFromRelatedParties	30000	usd
CY2023Q1	ZEOX	Revenues From Related Parties RevenuesFromRelatedParties	25000	usd
CY2024Q1	us-gaap	Revenues Revenues	1154000	usd
CY2023Q1	us-gaap	Revenues Revenues	1070000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	159000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	104000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	995000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	966000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2157000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3142000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1162000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2176000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	27000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	61000	usd
CY2024Q1	us-gaap	Other Income OtherIncome	149000	usd
CY2023Q1	ZEOX	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation	50000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1040000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2287000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6190794	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6190794	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7009549	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7009549	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1889000	usd
CY2023Q1	ZEOX	Sale Of Common Stock Value SaleOfCommonStockValue	100000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	975000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2287000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	677000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1241000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	773000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1040000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1508000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1040000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2287000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	156000	usd
CY2024Q1	ZEOX	Amortization Of Oid Promissory Notes AmortizationOfOidPromissoryNotes	6000	usd
CY2023Q1	ZEOX	Amortization Of Oid Promissory Notes AmortizationOfOidPromissoryNotes	37000	usd
CY2023Q1	ZEOX	Change In Commitments Fee Shortfall Obligation ChangeInCommitmentsFeeShortfallObligation	49000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	773000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	975000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	52000	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-10000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	209000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	41000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	33000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-372000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-110000	usd
CY2023Q1	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	10000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	313000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-575000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1283000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16000	usd
CY2023Q1	ZEOX	Funds Held In Escrow For Share Repurchase FundsHeldInEscrowForShareRepurchase	500000	usd
CY2024Q1	ZEOX	Payments On Finance Lease PaymentsOnFinanceLease	9000	usd
CY2023Q1	ZEOX	Payments On Finance Lease PaymentsOnFinanceLease	32000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	600000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1032000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-584000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2331000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1756000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3753000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1172000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1422000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	22000	usd
CY2024Q1	ZEOX	Reduction In Accounts Payable For Equipment Returned To Vendor ReductionInAccountsPayableForEquipmentReturnedToVendor	21000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zbk1OPMtgdDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 – <span id="xdx_828_z5yHkeqUriRi">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zeo ScientifiX, Inc. (“ZEO” or the “Company”) (f/k/a Organicell Regenerative Medicine, Inc.) was incorporated on August 9, 2011 in the State of Nevada under the name Bespoke Tricycles Inc. (changed to Biotech Products Services and Research, Inc. during September 2015 and to Organicell Regenerative Medicine, Inc., effective June 20, 2018). The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood (“RAAM Products”). Our RAAM Products and related services are principally used in the health care industry administered through doctors and clinics (“Providers”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 8, 2023, our board of directors and our stockholders holding a majority of the Company’s voting power, approved resolutions authorizing the Company to amend its Articles of Incorporation to change the name (“Name Change”) of the Company from Organicell Regenerative Medicine, Inc. to “Zeo ScientifiX, Inc.” On February 16, 2024, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the Company’s name from Organicell Regenerative Medicine, Inc. to Zeo ScientifiX Inc., effective February 20, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Name Change, the Company filed a Notification Form with the Financial Industry Regulatory Agency (“FINRA”) to effectuate the Name Change and to change the Company’s ticker symbol to “ZEOX” (“Ticker Change”). The Name Change and Ticker Change were effectuated in the marketplace by FINRA on March 5, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended January 31, 2024 and 2023, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation and wholly owned subsidiary, which was formed to sell the Company’s therapeutic products to Providers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s leading product, Zofin™ (also known as Organicell™ Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recently launched a service platform for its first autologous product called Patient Pure X™ (“PPX™”). PPX™ is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood. To date, revenues from PPX™ continue to be minimal.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has recently began to expand the use of its proprietary products in future formulations for a variety of topical use applications in the skin-care industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 7, 2023, the Company filed a certificate of amendment to its Articles of Incorporation to implement a reverse split of our issued and outstanding common stock on a one-for-200 basis (the “Reverse Split”). The Reverse Split was effective on November 28, 2023. The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. As a result, on the effective date of the Reverse Split, the stated capital on the Company’s balance sheet attributable to the Company’s common stock was reduced proportionately based on the Reverse Split ratio of one-for-200 and the additional paid-in capital account was credited with the amount by which the stated capital was reduced. All share and per share amounts referenced herein give effect to the Reverse Split as of the earliest period presented.</p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zqQPRESGKH66" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86B_zFtheWplq3r3">Concentrations of Risk</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_c20240131_pp0p0" title="FDIC limits per institutions">250,000</span> per institution. At January 31, 2024, the Company held a total of approximately $<span id="xdx_900_eus-gaap--CashUninsuredAmount_c20240131_pp0p0" title="Cash balances">712,000</span> of cash balances in one financial institution in excess of FDIC insurance coverage limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Major Customer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended January 31, 2024, the Company sold products and services totaling approximately $<span id="xdx_900_eus-gaap--Revenues_c20231101__20240131__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p0" title="Revenues">297,000</span> (<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_c20231101__20240131__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_zCuJVxtUDbZa" title="Concentration percentage">25.7%</span>) to a large distributor, approximately $<span id="xdx_903_eus-gaap--Revenues_c20231101__20240131__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p0" title="Revenues">125,000</span> (<span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_c20231101__20240131__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_zK4bJzaZTFLa" title="Concentration percentage">10.8%</span>) to another large distributor and approximately $<span id="xdx_903_eus-gaap--Revenues_c20231101__20240131__srt--MajorCustomersAxis__custom--IndividualMedicalPracticeMember_pp0p0" title="Revenues">201,000</span> (<span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_c20231101__20240131__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--IndividualMedicalPracticeMember_pdd" title="Concentration percentage">17.4%</span>) to an individual medical practice.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended January 31, 2023, the Company sold a total of approximately $<span id="xdx_902_eus-gaap--Revenues_c20221101__20230131__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p0" title="Revenues">303,000</span> (<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_c20221101__20230131__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_zhq2K1OEfx46" title="Concentration percentage">28.4%</span>) to a large distributor and approximately $<span id="xdx_901_eus-gaap--Revenues_c20221101__20230131__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p0" title="Revenues">295,000</span> (<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_c20221101__20230131__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_zQYQM6kIs0Ue" title="Concentration percentage">27.6%</span>) to another large distributor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	712000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	195000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zSJPwvtqRcP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_865_z58sI8x1OT33">Use of Estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity.</p>
CY2023Q1	ZEOX	Incremental Salary IncrementalSalary	429232	shares
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1040000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-575000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1508000	usd
CY2024Q1	ZEOX	Working Capital Deficit WorkingCapitalDeficit	2031000	usd
CY2024Q1	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	141000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	154000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	175000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	156000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	316000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	310000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	770000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	795000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	237000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	222000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	533000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	19000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	29000	usd
CY2024Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	127000	usd
CY2024Q1	ZEOX	Advances Payable AdvancesPayable	220897	usd
CY2023Q4	ZEOX	Advances Payable AdvancesPayable	220897	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	667000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	667000	usd
CY2024Q1	ZEOX	Lab Equipment And Supplies Payables LabEquipmentAndSuppliesPayables	245000	usd
CY2023Q4	ZEOX	Lab Equipment And Supplies Payables LabEquipmentAndSuppliesPayables	407000	usd
CY2024Q1	ZEOX	Clinical Trial Payables ClinicalTrialPayables	661000	usd
CY2023Q4	ZEOX	Clinical Trial Payables ClinicalTrialPayables	675000	usd
CY2024Q1	ZEOX	Legal Fees Payables LegalFeesPayables	237000	usd
CY2023Q4	ZEOX	Legal Fees Payables LegalFeesPayables	479000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	115000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	81000	usd
CY2024Q1	ZEOX	Accrued Irs Penalty AccruedIrsPenalty	92000	usd
CY2023Q4	ZEOX	Accrued Irs Penalty AccruedIrsPenalty	86000	usd
CY2024Q1	ZEOX	Accrued Commissions Payable AccruedCommissionsPayable	69000	usd
CY2023Q4	ZEOX	Accrued Commissions Payable AccruedCommissionsPayable	102000	usd
CY2024Q1	ZEOX	Construction Payables ConstructionPayables	9000	usd
CY2023Q4	ZEOX	Construction Payables ConstructionPayables	9000	usd
CY2024Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	124000	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	106000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2219000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2612000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	725000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	725000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	62000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	68000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	663000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	657000	usd
CY2024Q1	us-gaap	Share Price SharePrice	0.001
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	100000	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	12.20
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	100000	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	12.20
CY2024Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	773000	usd
CY2023Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	631000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4108000	usd
CY2023	ZEOX	Deferred Revenue Invoiced Description DeferredRevenueInvoicedDescription	As of October 31, 2023, $101,000 of product inventory was invoiced and delivered reducing the deferred revenue amount to $399,000.
CY2024Q1	ZEOX	Deferred Revenue Invoiced Description DeferredRevenueInvoicedDescription	During the period ended January 31, 2024, $81,000 of product inventory was invoiced and delivered, further reducing the deferred revenue balance to $318,000 as of that date.
CY2024Q1	ZEOX	Initial Purchase Order InitialPurchaseOrder	403000	usd
CY2024Q1	ZEOX	Advances Advances	318000	usd
CY2023Q4	ZEOX	Advances Advances	399000	usd
CY2024Q1	ZEOX	Sales To Customers Not Yet Delivered SalesToCustomersNotYetDelivered	89000	usd
CY2023Q4	ZEOX	Sales To Customers Not Yet Delivered SalesToCustomersNotYetDelivered	98000	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	810000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	497000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer

Files In Submission

Name	View Source	Status
0001829126-24-001677-index-headers.html	Edgar Link	pending
0001829126-24-001677-index.html	Edgar Link	pending
0001829126-24-001677.txt	Edgar Link	pending
0001829126-24-001677-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zeoscientifixinc_10q.htm	Edgar Link	pending
zeoscientifixinc_ex31-1.htm	Edgar Link	pending
zeoscientifixinc_ex31-2.htm	Edgar Link	pending
zeoscientifixinc_ex32-1.htm	Edgar Link	pending
zeoscientifixinc_ex32-2.htm	Edgar Link	pending
zeox-20240131.xsd	Edgar Link	pending
zeox-20240131_def.xml	Edgar Link	unprocessable
zeox-20240131_lab.xml	Edgar Link	unprocessable
zeox-20240131_pre.xml	Edgar Link	unprocessable
zeoscientifixinc_10q_htm.xml	Edgar Link	completed
zeox-20240131_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZEOX
Zeo ScientifiX, Inc. Stock $zeox

2024 Q1 Form 10-Q Financial Statement

#000182912624001677 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZEOX Zeo ScientifiX, Inc. Stock $zeox

2024 Q1 Form 10-Q Financial Statement

#000182912624001677 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZEOX
Zeo ScientifiX, Inc. Stock $zeox